The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The evolving landscape of treatment for anemia in LR-MDS: newly available agents
Esther Oliva, MD, London North West University Healthcare NHS Trust, London, UK, comments on the evolving landscape of treatment for anemia in lower-risk myelodysplastic syndromes (LR-MDS). Dr Oliva highlights the introduction of luspatercept in the first-line and second-line setting, as well as imetelstat for resistant or refractory patients. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well in the past two to three years we have had the availability of new treatments for lower risk MDS for the treatment of anemia. So we’ve seen first luspatercept in second line for MDS with ring sideroblast and then we we now have the availability of luspatercept in first-line treatment where we only had erythropoietin alpha. Furthermore in second-line treatment for those patients that are resistant refractory to other treatments we also have imetelstat which has given us more choice of treatment for our patients...
Well in the past two to three years we have had the availability of new treatments for lower risk MDS for the treatment of anemia. So we’ve seen first luspatercept in second line for MDS with ring sideroblast and then we we now have the availability of luspatercept in first-line treatment where we only had erythropoietin alpha. Furthermore in second-line treatment for those patients that are resistant refractory to other treatments we also have imetelstat which has given us more choice of treatment for our patients. So this is aiming at reducing transfusion requirement, but also improving several different types of outcomes in lower risk MDS, which includes probably survival. We still don’t have a definite answer, but also health-related quality of life outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
